Patient
|
MC1 (mGy)
|
MC2 (mGy)
|
gMC3 (mGy)
|
SMIRD (mGy)
|
---|
P8
|
1123
|
225
|
718
|
46
|
P9
|
684
|
202
|
408
|
40
|
- gMC3 uses the patient-specific Tc-99m-anti-granulocyte-based active bone marrow VOI. MC1 assumes a physiological active bone marrow distribution, while MC2 assumes a physiological distribution, however with displacement of active bone marrow from the direct site of metastases